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Dear Editor,
We have read the article ” Epicardial fat thickness(EFT) 
in patients with rheumatoid arthritis” written by Erdem 
et al. with a great interest.1 The authors aimed to explain 
the relationship between epicardial fat thickness and 
clinical and echocardiographic parameters in patients 
with rheumatoid arthritis. They concluded that  EFT  as 
an indicator of  cardiovascular involvement was higher 
in rheumatoid arthritis patients. Thanks to the authors 
for their contribution of  the present study which is suc-
cessfully designed and documented.
 
Epicardial tissue makes active endocrine organ function 
which produces several markers involved in oxidative 
stress, endothelial dysfunction, atherosclerosis and in-
flammation,2,3. Increased epicardial adiposity can lead 
to  cardiovascular diseases due to endocrine actions that 
include increased production of  reactive oxygen spe-
cies, atherogenic and inflammatory cytokines. Various 
studies have highlighted EFT is also clinically related 
to hypertension, type 2 diabetes, metabolic syndrome, 
dyslipidemia, nonalcoholic fatty liver disease, and 
chronic kidney disease. EFT is also a cardiometabolic 
risk factor in various inflammatory diseases and is also 
independently associated with psoriasis.4 EFT may be 
included among the clinical parameters associated with 
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OSA severity. The association of  EFT with OSA, both 
cardiovascular risk factors, is independent of  obesity as 
defined by classical measures5. 
Echocardiographic epicardial fat measurement in both 
clinical and research scenarios has several advantages, 
including its low cost, easy accessibility, rapid applicabil-
ity, and good reproducibility. However, more evidence 
is necessary to evaluate whether echocardiographic ep-
icardial fat thickness may become a routine way of  as-
sessing cardiovascular risk in a clinical setting6. In pres-
ent study, EFT was calculated on the free wall of  the 
right ventricle in the still images obtained at end diastole 
the parasternal long-axis view, using the aortic annulus 
as an anatomic reference. However, second image as 
short axis view may be add useful information about 
EFT values.Then, the mean value of  two images ob-
tained in the parasternal long-axis and short-axis views 
should be  measured.Secondly, the echocardiography 
method might not be the optimal technique for quanti-
fication of  epicardial tissue. The gold standard in eval-
uating EFT is magnetic resonance imaging (MRI); the 
lack of  MRI use is one of  the limitations of  the present 
study. After that, because echocardiography measures 
EFT linearly, echocardiographic EFT may not reflect 
the total epicardial fat volume exactly.  EFT has a 3-di-
mensional distribution and  two-dimensional echocar-
diography  cannot give adequate window of  all cardiac 
segments especially in obese subjects and is highly de-
pendent on acoustic windows2. In this point of  view, it 
would be better to give interobserver and intraobserver 
variability for EAT measurement in the current study7. 
As a conclusion, EFT may provide information to cli-
nicians about the systemic inflammation. So, we believe 
that these findings will evaluate further studies about 
EFT on cardiovascular risk in systemic inflammatory 
disease patients.
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